Download Supplemental References

Supplemental Information
References S76-S264
S76.
S77.
S78.
S79.
S80.
S81.
S82.
S83.
S84.
S85.
S86.
S87.
Borsig L, Wong R, Hynes RO, Varki NM, Varki A. Synergistic effects of Land P-selectin in facilitating tumor metastasis can involve non-mucin
ligands and implicate leukocytes as enhancers of metastasis. Proc Natl
Acad Sci U S A 2002;99:2193-8.
Biancone L, Araki M, Araki K, Vassalli P, Stamenkovic I. Redirection of
tumor metastasis by expression of E-selectin in vivo. J Exp Med
1996;183:581-7.
Drake RR, Schwegler EE, Malik G, Diaz J, Block T, Mehta A, Semmes OJ.
Lectin capture strategies combined with mass spectrometry for the
discovery of serum glycoprotein biomarkers. Mol Cell Proteomics
2006;5:1957-67.
Taniguchi N, Hancock W, Lubman DM, Rudd PM. The second golden age
of glycomics: from functional glycomics to clinical applications. J
Proteome Res 2009;8:425-6.
Hortin GL, Sviridov D, Anderson NL. High-abundance polypeptides of
the human plasma proteome comprising the top 4 logs of polypeptide
abundance. Clin Chem 2008;54:1608-16.
Qian WJ, Kaleta DT, Petritis BO, Jiang H, Liu T, Zhang X, et al. Enhanced
detection of low abundance human plasma proteins using a tandem
IgY12-SuperMix immunoaffinity separation strategy. Mol Cell
Proteomics 2008;7:1963-73.
Comunale MA, Wang M, Hafner J, Krakover J, Rodemich L, Kopenhaver
B, et al. Identification and development of fucosylated glycoproteins as
biomarkers of primary hepatocellular carcinoma. J Proteome Res
2009;8:595-602.
Kullolli M, Hancock WS, Hincapie M. Preparation of a high-performance
multi-lectin affinity chromatography (HP-M-LAC) adsorbent for the
analysis of human plasma glycoproteins. J Sep Sci 2008;31:2733-9.
Jung K, Cho W, Regnier FE. Glycoproteomics of plasma based on narrow
selectivity lectin affinity chromatography. J Proteome Res 2009;8:64350.
Yang N, Li DF, Feng L, Xiang Y, Liu W, Sun H, Wang DC. Structural basis
for the tumor cell apoptosis-inducing activity of an antitumor lectin
from the edible mushroom Agrocybe aegerita. J Mol Biol 2009;387:694705.
Maley F, Trimble RB, Tarentino AL, Plummer TH, Jr. Characterization of
glycoproteins and their associated oligosaccharides through the use of
endoglycosidases. Anal Biochem 1989;180:195-204.
Kaji H, Saito H, Yamauchi Y, Shinkawa T, Taoka M, Hirabayashi J, et al.
Lectin affinity capture, isotope-coded tagging and mass spectrometry to
identify N-linked glycoproteins. Nat Biotechnol 2003;21:667-72.
S88.
Xiong L, Andrews D, Regnier F. Comparative proteomics of
glycoproteins based on lectin selection and isotope coding. J Proteome
Res 2003;2:618-25.
S89. Calvano CD, Zambonin CG, Jensen ON. Assessment of lectin and HILIC
based enrichment protocols for characterization of serum
glycoproteins by mass spectrometry. J Proteomics 2008;71:304-17.
S90. Heo SH, Lee SJ, Ryoo HM, Park JY, Cho JY. Identification of putative
serum glycoprotein biomarkers for human lung adenocarcinoma by
multilectin affinity chromatography and LC-MS/MS. Proteomics
2007;7:4292-302.
S91. Plavina T, Wakshull E, Hancock WS, Hincapie M. Combination of
abundant protein depletion and multi-lectin affinity chromatography
(M-LAC) for plasma protein biomarker discovery. J Proteome Res
2007;6:662-71.
S92. Yang Z, Harris LE, Palmer-Toy DE, Hancock WS. Multilectin affinity
chromatography for characterization of multiple glycoprotein
biomarker candidates in serum from breast cancer patients. Clin Chem
2006;52:1897-905.
S93. Cho W, Jung K, Regnier FE. Use of glycan targeting antibodies to identify
cancer-associated glycoproteins in plasma of breast cancer patients.
Anal Chem 2008;80:5286-92.
S94. Yang Z, Hancock WS. Approach to the comprehensive analysis of
glycoproteins isolated from human serum using a multi-lectin affinity
column. J Chromatogr A 2004;1053:79-88.
S95. Abbott KL, Aoki K, Lim JM, Porterfield M, Johnson R, O'Regan RM, et al.
Targeted glycoproteomic identification of biomarkers for human breast
carcinoma. J Proteome Res 2008;7:1470-80.
S96. Lee YC, Block G, Chen H, Folch-Puy E, Foronjy R, Jalili R, et al. One-step
isolation of plasma membrane proteins using magnetic beads with
immobilized concanavalin A. Protein Expr Purif 2008;62:223-9.
S97. Bond MR, Kohler JJ. Chemical methods for glycoprotein discovery. Curr
Opin Chem Biol 2007;11:52-8.
S98. Zhang H, Li XJ, Martin DB, Aebersold R. Identification and quantification
of N-linked glycoproteins using hydrazide chemistry, stable isotope
labeling and mass spectrometry. Nat Biotechnol 2003;21:660-6.
S99. Tian Y, Zhou Y, Elliott S, Aebersold R, Zhang H. Solid-phase extraction of
N-linked glycopeptides. Nat Protoc 2007;2:334-9.
S100. Sun B, Ranish JA, Utleg AG, White JT, Yan X, Lin B, Hood L. Shotgun
glycopeptide capture approach coupled with mass spectrometry for
comprehensive glycoproteomics. Mol Cell Proteomics 2007;6:141-9.
S101. Sparbier K, Koch S, Kessler I, Wenzel T, Kostrzewa M. Selective isolation
of glycoproteins and glycopeptides for MALDI-TOF MS detection
supported by magnetic particles. J Biomol Tech 2005;16:407-13.
S102. Sparbier K, Asperger A, Resemann A, Kessler I, Koch S, Wenzel T, et al.
Analysis of glycoproteins in human serum by means of glycospecific
S103.
S104.
S105.
S106.
S107.
S108.
S109.
S110.
S111.
S112.
S113.
S114.
S115.
magnetic bead separation and LC-MALDI-TOF/TOF analysis with
automated glycopeptide detection. J Biomol Tech 2007;18:252-8.
Zhang H, Loriaux P, Eng J, Campbell D, Keller A, Moss P, et al. UniPep--a
database for human N-linked glycosites: a resource for biomarker
discovery. Genome Biol 2006;7:R73.
Laughlin ST, Bertozzi CR. Metabolic labeling of glycans with azido
sugars and subsequent glycan-profiling and visualization via
Staudinger ligation. Nat Protoc 2007;2:2930-44.
Goetz JA, Mechref Y, Kang P, Jeng MH, Novotny MV. Glycomic profiling of
invasive and non-invasive breast cancer cells. Glycoconj J 2009;26:11731.
Yamada K, Kinoshita M, Hayakawa T, Nakaya S, Kakehi K. Comparative
studies on the structural features of O-glycans between leukemia and
epithelial cell lines. J Proteome Res 2009;8:521-37.
Li B, An HJ, Kirmiz C, Lebrilla CB, Lam KS, Miyamoto S. Glycoproteomic
analyses of ovarian cancer cell lines and sera from ovarian cancer
patients show distinct glycosylation changes in individual proteins. J
Proteome Res 2008;7:3776-88.
Bereman MS, Williams TI, Muddiman DC. Development of a nanoLC LTQ
orbitrap mass spectrometric method for profiling glycans derived from
plasma from healthy, benign tumor control, and epithelial ovarian
cancer patients. Anal Chem 2009;81:1130-6.
de Leoz ML, An HJ, Kronewitter S, Kim J, Beecroft S, Vinall R, et al.
Glycomic approach for potential biomarkers on prostate cancer:
profiling of N-linked glycans in human sera and pRNS cell lines. Dis
Markers 2008;25:243-58.
Kirmiz C, Li B, An HJ, Clowers BH, Chew HK, Lam KS, et al. A serum
glycomics approach to breast cancer biomarkers. Mol Cell Proteomics
2007;6:43-55.
Anderson L, Hunter CL. Quantitative mass spectrometric multiple
reaction monitoring assays for major plasma proteins. Mol Cell
Proteomics 2006;5:573-88.
Stahl-Zeng J, Lange V, Ossola R, Eckhardt K, Krek W, Aebersold R,
Domon B. High sensitivity detection of plasma proteins by multiple
reaction monitoring of N-glycosites. Mol Cell Proteomics 2007;6:180917.
Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM, et
al. Multi-site assessment of the precision and reproducibility of
multiple reaction monitoring-based measurements of proteins in
plasma. Nat Biotechnol 2009;27:633-41.
Anderson NL, Anderson NG, Haines LR, Hardie DB, Olafson RW, Pearson
TW. Mass spectrometric quantitation of peptides and proteins using
Stable Isotope Standards and Capture by Anti-Peptide Antibodies
(SISCAPA). J Proteome Res 2004;3:235-44.
Ahn YH, Lee JY, Kim YS, Ko JH, Yoo JS. Quantitative Analysis of an
Aberrant Glycoform of TIMP1 from Colon Cancer Serum by L-PHA-
S116.
S117.
S118.
S119.
S120.
S121.
S122.
S123.
S124.
S125.
S126.
S127.
S128.
S129.
Enrichment and SISCAPA with MRM Mass Spectrometry. J Proteome Res
2009.
Anderson NL, Jackson A, Smith D, Hardie D, Borchers C, Pearson TW.
SISCAPA peptide enrichment on magnetic beads using an in-line bead
trap device. Mol Cell Proteomics 2009;8:995-1005.
Chen S, LaRoche T, Hamelinck D, Bergsma D, Brenner D, Simeone D, et
al. Multiplexed analysis of glycan variation on native proteins captured
by antibody microarrays. Nat Methods 2007;4:437-44.
Wu YM, Nowack D, Omenn G, Haab B. Mucin glycosylation is altered by
pro-inflammatory signaling in pancreatic-cancer cells. J Proteome Res
2009.
Anderson L. A Survey of Clinical Assays for Proteins in Plasma and Serum.
Clinical Chemistry 2009.
Presant CA, Kornfeld S. Characterization of the cell surface receptor for
the Agaricus bisporus hemagglutinin. J Biol Chem 1972;247:6937-45.
Sueyoshi S, Yamamoto K, Osawa T. Carbohydrate binding specificity of a
beetle (Allomyrina dichotoma) lectin. J Biochem 1988;103:894-9.
Ahmed H, Chatterjee BP. Further characterization and immunochemical
studies on the carbohydrate specificity of jackfruit (Artocarpus
integrifolia) lectin. J Biol Chem 1989;264:9365-72.
Kaladas PM, Kabat EA, Iglesias JL, Lis H, Sharon N. Immunochemical
studies on the combining site of the D-galactose/N-acetyl-Dgalactosamine specific lectin from Erythrina cristagalli seeds. Arch
Biochem Biophys 1982;217:624-37.
Swamy MJ, Gupta D, Mahanta SK, Surolia A. Further characterization of
the saccharide specificity of peanut (Arachis hypogaea) agglutinin.
Carbohydr Res 1991;213:59-67.
Torres BV, McCrumb DK, Smith DF. Glycolipid-lectin interactions:
reactivity of lectins from Helix pomatia, Wisteria floribunda, and
Dolichos biflorus with glycolipids containing N-acetylgalactosamine.
Arch Biochem Biophys 1988;262:1-11.
Piller V, Piller F, Cartron JP. Comparison of the carbohydrate-binding
specificities of seven N-acetyl-D-galactosamine-recognizing lectins. Eur
J Biochem 1990;191:461-6.
Roberts DD, Goldstein IJ. Reexamination of the carbohydrate binding
stoichiometry of lima bean lectin. Arch Biochem Biophys 1984;230:31620.
Shen ZM, Shi WX, Sun C, Yang JT. Conformation and activity of mannoseand N-acetylgalactosamine-specific lectins from Vicia villosa seeds.
Biochimie 1993;75:949-54.
Crowley JF, Goldstein IJ, Arnarp J, Lonngren J. Carbohydrate binding
studies on the lectin from Datura stramonium seeds. Arch Biochem
Biophys 1984;231:524-33.
S130. Wood C, Kabat EA, Ebisu S, Goldstein IJ. An immunochemical study of
the combining sites of the second lectin isolated from Bandeiraea
simplicifolia (BS II). Ann Immunol (Paris) 1978;129:143-58.
S131. Nachbar MS, Oppenheim JD, Thomas JO. Lectins in the U.S. Diet.
Isolation and characterization of a lectin from the tomato (Lycopersicon
esculentum). J Biol Chem 1980;255:2056-61.
S132. Allen AK, Neuberger A, Sharon N. The purification, composition and
specificity of wheat-germ agglutinin. Biochem J 1973;131:155-62.
S133. Peters BP, Ebisu S, Goldstein IJ, Flashner M. Interaction of wheat germ
agglutinin with sialic acid. Biochemistry 1979;18:5505-11.
S134. Yamamoto K, Tsuji T, Matsumoto I, Osawa T. Structural requirements
for the binding of oligosaccharides and glycopeptides to immobilized
wheat germ agglutinin. Biochemistry 1981;20:5894-9.
S135. Debray H, Decout D, Strecker G, Spik G, Montreuil J. Specificity of twelve
lectins towards oligosaccharides and glycopeptides related to Nglycosylproteins. Eur J Biochem 1981;117:41-55.
S136. Shibuya N, Goldstein IJ, Broekaert WF, Nsimba-Lubaki M, Peeters B,
Peumans WJ. The elderberry (Sambucus nigra L.) bark lectin recognizes
the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J Biol Chem
1987;262:1596-601.
S137. Kornfeld K, Reitman ML, Kornfeld R. The carbohydrate-binding
specificity of pea and lentil lectins. Fucose is an important determinant.
J Biol Chem 1981;256:6633-40.
S138. Debray H, Montreuil J. Aleuria aurantia agglutinin. A new isolation
procedure and further study of its specificity towards various
glycopeptides and oligosaccharides. Carbohydr Res 1989;185:15-26.
S139. Horejsi V, Ticha M, Kocourek J. Studies on lectins. XXXII. Application of
affinity electrophoresis to the study of the interaction of lectins and
their derivatives with sugars. Biochim Biophys Acta 1977;499:301-8.
S140. Pereira ME, Kabat EA. Specificity of purified hemagglutinin (lectin) from
Lotus tetragonolobus. Biochemistry 1974;13:3184-92.
S141. Sughii S, Kabat EA, Baer HH. Further immunochemical studies on the
combining sites of Lotus tetragonolobus and Ulex europaeus I and II
lectins. Carbohydr Res 1982;99:99-101.
S142. Ravindranath MH, Higa HH, Cooper EL, Paulson JC. Purification and
characterization of an O-acetylsialic acid-specific lectin from a marine
crab Cancer antennarius. J Biol Chem 1985;260:8850-6.
S143. Wang WC, Cummings RD. The immobilized leukoagglutinin from the
seeds of Maackia amurensis binds with high affinity to complex-type
Asn-linked oligosaccharides containing terminal sialic acid-linked
alpha-2,3 to penultimate galactose residues. J Biol Chem
1988;263:4576-85.
S144. Kolberg J, Michaelsen TE, Sletten K. Properties of a lectin purified from
the seeds of Cicer arietinum. Hoppe Seylers Z Physiol Chem
1983;364:655-64.
S145. Petryniak J, Goldstein IJ. Evonymus europaea lectin. Methods Enzymol
1987;138:552-61.
S146. Cummings RD, Kornfeld S. Characterization of the structural
determinants required for the high affinity interaction of asparaginelinked oligosaccharides with immobilized Phaseolus vulgaris
leukoagglutinating and erythroagglutinating lectins. J Biol Chem
1982;257:11230-4.
S147. Nemec M, Drimalova D, Horejsi V, Vanak J, Bartek J, Viklicky V. Murine
monoclonal antibodies to human A erythrocytes: differential reactivity
with N-acetyl-D-galactosamine. Vox Sang 1987;52:125-8.
S148. Vanak J, Drimalova D, Smyslova O, Nemec M, Viklicky V, Wisniewski K.
Detection of blood group A antigen expression in human colon cancer
using monoclonal antibodies with different specificities. Neoplasma
1989;36:479-88.
S149. Nystrom K, Grahn A, Lindh M, Brytting M, Mandel U, Larson G, Olofsson
S. Virus-induced transcriptional activation of host FUT genes associated
with neo-expression of Ley in cytomegalovirus-infected and sialyl-Lex
in varicella-zoster virus-infected diploid human cells. Glycobiology
2007;17:355-66.
S150. Rye PD, Bovin NV, Vlasova EV, Molodyk AA, Baryshnikov A, Kreutz FT, et
al. Summary report on the ISOBM TD-6 workshop: analysis of 20
monoclonal antibodies against Sialyl Lewisa and related antigens.
Montreux, Switzerland, September 19-24, 1997. Tumour Biol
1998;19:390-420.
S151. Shi CS, Shi GY, Hsiao SM, Kao YC, Kuo KL, Ma CY, et al. Lectin-like domain
of thrombomodulin binds to its specific ligand Lewis Y antigen and
neutralizes lipopolysaccharide-induced inflammatory response. Blood
2008;112:3661-70.
S152. Lund-Johansen F, Olweus J, Horejsi V, Skubitz KM, Thompson JS, Vilella
R, Symington FW. Activation of human phagocytes through
carbohydrate antigens (CD15, sialyl-CD15, CDw17, and CDw65). J
Immunol 1992;148:3221-9.
S153. Mitsuoka C, Kawakami-Kimura N, Kasugai-Sawada M, Hiraiwa N, Toda
K, Ishida H, et al. Sulfated sialyl Lewis X, the putative L-selectin ligand,
detected on endothelial cells of high endothelial venules by a distinct
set of anti-sialyl Lewis X antibodies. Biochem Biophys Res Commun
1997;230:546-51.
S154. Yeh CY, Lin CN, Chang CF, Lin CH, Lien HT, Chen JY, Chia JS. C-terminal
repeats of Clostridium difficile toxin A induce production of chemokine
and adhesion molecules in endothelial cells and promote migration of
leukocytes. Infect Immun 2008;76:1170-8.
S155. Hemmerich S, Butcher EC, Rosen SD. Sulfation-dependent recognition of
high endothelial venules (HEV)-ligands by L-selectin and MECA 79, and
adhesion-blocking monoclonal antibody. J Exp Med 1994;180:2219-26.
S156. Saldova R, Wormald MR, Dwek RA, Rudd PM. Glycosylation changes on
serum glycoproteins in ovarian cancer may contribute to disease
pathogenesis. Dis Markers 2008;25:219-32.
S157. Saldova R, Royle L, Radcliffe CM, Abd Hamid UM, Evans R, Arnold JN, et
al. Ovarian cancer is associated with changes in glycosylation in both
acute-phase proteins and IgG. Glycobiology 2007;17:1344-56.
S158. Zhang Z, Bast RC, Jr., Yu Y, Li J, Sokoll LJ, Rai AJ, et al. Three biomarkers
identified from serum proteomic analysis for the detection of early
stage ovarian cancer. Cancer Res 2004;64:5882-90.
S159. Nosov V, Su F, Amneus M, Birrer M, Robins T, Kotlerman J, et al.
Validation of serum biomarkers for detection of early-stage ovarian
cancer. Am J Obstet Gynecol 2009;200:639 e1-5.
S160. El-Akawi ZJ, Al-Hindawi FK, Bashir NA. Alpha-1 antitrypsin (alpha1-AT)
plasma levels in lung, prostate and breast cancer patients. Neuro
Endocrinol Lett 2008;29:482-4.
S161. Abdul-Rahman PS, Lim BK, Hashim OH. Expression of high-abundance
proteins in sera of patients with endometrial and cervical cancers:
analysis using 2-DE with silver staining and lectin detection methods.
Electrophoresis 2007;28:1989-96.
S162. Abdullah M, Schultz H, Kahler D, Branscheid D, Dalhoff K, Zabel P, et al.
Expression of the acute phase protein haptoglobin in human lung
cancer and tumor-free lung tissues. Pathol Res Pract 2009;205:639-47.
S163. Moore LE, Fung ET, McGuire M, Rabkin CC, Molinaro A, Wang Z, et al.
Evaluation of apolipoprotein A1 and posttranslationally modified forms
of transthyretin as biomarkers for ovarian cancer detection in an
independent study population. Cancer Epidemiol Biomarkers Prev
2006;15:1641-6.
S164. Schaub NP, Jones KJ, Nyalwidhe JO, Cazares LH, Karbassi ID, Semmes OJ,
et al. Serum proteomic biomarker discovery reflective of stage and
obesity in breast cancer patients. J Am Coll Surg 2009;208:970-8;
discussion 8-80.
S165. Petrik V, Saadoun S, Loosemore A, Hobbs J, Opstad KS, Sheldon J, et al.
Serum alpha 2-HS glycoprotein predicts survival in patients with
glioblastoma. Clin Chem 2008;54:713-22.
S166. Kalabay L, Jakab L, Prohaszka Z, Fust G, Benko Z, Telegdy L, et al. Human
fetuin/alpha2HS-glycoprotein level as a novel indicator of liver cell
function and short-term mortality in patients with liver cirrhosis and
liver cancer. Eur J Gastroenterol Hepatol 2002;14:389-94.
S167. Jeong DH, Kim HK, Prince AE, Lee DS, Kim YN, Han J, Kim KT. Plasma
proteomic analysis of patients with squamous cell carcinoma of the
uterine cervix. J Gynecol Oncol 2008;19:173-80.
S168. Gast MC, Van Gils CH, Wessels LF, Harris N, Bonfrer JM, Rutgers EJ, et al.
Serum protein profiling for diagnosis of breast cancer using SELDI-TOF
MS. Oncol Rep 2009;22:205-13.
S169. Kang HJ, Koh KH, Yang E, You KT, Kim HJ, Paik YK, Kim H. Differentially
expressed proteins in gastrointestinal stromal tumors with KIT and
PDGFRA mutations. Proteomics 2006;6:1151-7.
S170. Gerner C, Steinkellner W, Holzmann K, Gsur A, Grimm R, Ensinger C, et
al. Elevated plasma levels of crosslinked fibrinogen gamma-chain dimer
indicate cancer-related fibrin deposition and fibrinolysis. Thromb
Haemost 2001;85:494-501.
S171. Dowling P, O'Driscoll L, Meleady P, Henry M, Roy S, Ballot J, et al. 2-D
difference gel electrophoresis of the lung squamous cell carcinoma
versus normal sera demonstrates consistent alterations in the levels of
ten specific proteins. Electrophoresis 2007;28:4302-10.
S172. Kolwijck E, Engelke UF, van der Graaf M, Heerschap A, Blom HJ,
Hadfoune M, et al. N-acetyl resonances in in vivo and in vitro NMR
spectroscopy of cystic ovarian tumors. NMR Biomed 2009.
S173. Imre T, Kremmer T, Heberger K, Molnar-Szollosi E, Ludanyi K, Pocsfalvi
G, et al. Mass spectrometric and linear discriminant analysis of Nglycans of human serum alpha-1-acid glycoprotein in cancer patients
and healthy individuals. J Proteomics 2008;71:186-97.
S174. Goufman EI, Moshkovskii SA, Tikhonova OV, Lokhov PG, Zgoda VG,
Serebryakova MV, et al. Two-dimensional electrophoretic proteome
study of serum thermostable fraction from patients with various tumor
conditions. Biochemistry (Mosc) 2006;71:354-60.
S175. Gertz MA, Hayman SR, Buadi FK. Transplantation for IgM amyloidosis
and IgM myeloma. Clin Lymphoma Myeloma 2009;9:77-9.
S176. Elsawa SF, Ansell SM. Cytokines in the microenvironment of
Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma
2009;9:43-5.
S177. Ueda K, Fukase Y, Katagiri T, Ishikawa N, Irie S, Sato TA, et al. Targeted
serum glycoproteomics for the discovery of lung cancer-associated
glycosylation disorders using lectin-coupled ProteinChip arrays.
Proteomics 2009;9:2182-92.
S178. Chen J, Anderson M, Misek DE, Simeone DM, Lubman DM.
Characterization of apolipoprotein and apolipoprotein precursors in
pancreatic cancer serum samples via two-dimensional liquid
chromatography and mass spectrometry. J Chromatogr A
2007;1162:117-25.
S179. Welinder C, Jansson B, Ferno M, Olson H, Baldetorp B. Expression of
Helix pomatia lectin binding glycoproteins in women with breast
cancer in relationship to their blood group phenotypes. J Proteome Res
2009;8:782-7.
S180. Kanoh Y, Egawa S, Baba S, Akahoshi T. Associations of IgG N-linked
oligosaccharide chains and proteases in sera of prostate cancer patients
with and without alpha2-macroglobulin deficiency. J Clin Lab Anal
2009;23:125-31.
S181. Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, et al. The multiplex
bead array approach to identifying serum biomarkers associated with
breast cancer. Breast Cancer Res 2009;11:R22.
S182. Yamamoto N, Suyama H, Nakazato H, Yamamoto N, Koga Y.
Immunotherapy of metastatic colorectal cancer with vitamin D-binding
protein-derived macrophage-activating factor, GcMAF. Cancer Immunol
Immunother 2008;57:1007-16.
S183. Kabbage M, Chahed K, Hamrita B, Guillier CL, Trimeche M, Remadi S, et
al. Protein alterations in infiltrating ductal carcinomas of the breast as
detected by nonequilibrium pH gradient electrophoresis and mass
spectrometry. J Biomed Biotechnol 2008;2008:564127.
S184. Ishida Y, Yamashita K, Sasaki H, Takajou I, Kubuki Y, Morishita K, et al.
Activation of complement system in adult T-cell leukemia (ATL) occurs
mainly through lectin pathway: a serum proteomic approach using
mass spectrometry. Cancer Lett 2008;271:167-77.
S185. Licastro F, Bertaccini A, Porcellini E, Chiappelli M, Pernetti R,
Sanguedolce F, et al. Alpha 1 antichymotrypsin genotype is associated
with increased risk of prostate carcinoma and PSA levels. Anticancer
Res 2008;28:395-9.
S186. Soiland H, Skaland I, Varhaug JE, Korner H, Janssen EA, Gudlaugsson E,
et al. Co-expression of estrogen receptor alpha and Apolipoprotein D in
node positive operable breast cancer--possible relevance for survival
and effects of adjuvant tamoxifen in postmenopausal patients. Acta
Oncol 2009;48:514-21.
S187. Vizoso FJ, Rodriguez M, Altadill A, Gonzalez-Dieguez ML, Linares A,
Gonzalez LO, et al. Liver expression of steroid hormones and
Apolipoprotein D receptors in hepatocellular carcinoma. World J
Gastroenterol 2007;13:3221-7.
S188. Beecken WD, Engl T, Ringel EM, Camphausen K, Michaelis M, Jonas D, et
al. An endogenous inhibitor of angiogenesis derived from a transitional
cell carcinoma: clipped beta2-glycoprotein-I. Ann Surg Oncol
2006;13:1241-51.
S189. Itoh Y, Inuzuka K, Kohno I, Wada H, Shiku H, Ohkura N, Kato H. Highly
increased plasma concentrations of the nicked form of beta(2)
glycoprotein I in patients with leukemia and with lupus anticoagulant:
measurement with a monoclonal antibody specific for a nicked form of
domain V. J Biochem 2000;128:1017-24.
S190. Matsuguchi T, Okamura S, Aso T, Takahashi K, Sata T, Niho Y.
Interleukin 6 and tumor necrosis factor fully activate liver-specific gene
expression of the alpha chain of C4b-binding protein. Biochem Int
1991;23:979-85.
S191. Holmberg MT, Blom AM, Meri S. Regulation of complement classical
pathway by association of C4b-binding protein to the surfaces of SK-OV3 and Caov-3 ovarian adenocarcinoma cells. J Immunol 2001;167:935-9.
S192. Gutfeld O, Prus D, Ackerman Z, Dishon S, Linke RP, Levin M, UrieliShoval S. Expression of serum amyloid A, in normal, dysplastic, and
S193.
S194.
S195.
S196.
S197.
S198.
S199.
S200.
S201.
S202.
S203.
S204.
S205.
neoplastic human colonic mucosa: implication for a role in colonic
tumorigenesis. J Histochem Cytochem 2006;54:63-73.
Himmelfarb M, Klopocki E, Grube S, Staub E, Klaman I, Hinzmann B, et
al. ITIH5, a novel member of the inter-alpha-trypsin inhibitor heavy
chain family is downregulated in breast cancer. Cancer Lett
2004;204:69-77.
Paris S, Sesboue R, Delpech B, Chauzy C, Thiberville L, Martin JP, et al.
Inhibition of tumor growth and metastatic spreading by overexpression
of inter-alpha-trypsin inhibitor family chains. Int J Cancer 2002;97:61520.
Bourguignon J, Borghi H, Sesboue R, Diarra-Mehrpour M, Bernaudin JF,
Metayer J, et al. Immunohistochemical distribution of inter-alphatrypsin inhibitor chains in normal and malignant human lung tissue. J
Histochem Cytochem 1999;47:1625-32.
Kobayashi H, Gotoh J, Hirashima Y, Terao T. Inter-alpha-trypsin
inhibitor bound to tumor cells is cleaved into the heavy chains and the
light chain on the cell surface. J Biol Chem 1996;271:11362-7.
Turner RB, Haynes HA, Granter SR, Miller DM. Acquired cutis laxa
following urticarial vasculitis associated with IgA myeloma. J Am Acad
Dermatol 2009;60:1052-7.
Teng HW, Chen PM, Yang YH, Gau JP. The prolonged activated partial
thromboplastin time at diagnosis indicates less favorable prognosis in
IgA myeloma. Jpn J Clin Oncol 2007;37:609-14.
Kovacova E, Kinova S, Duris I, Remkova A. General changes in
hemostasis in gastric cancer. Bratisl Lek Listy 2009;110:215-21.
Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, et al.
Protein biomarker identification in the CSF of patients with CNS
lymphoma. J Clin Oncol 2008;26:96-105.
Tian M, Cui YZ, Song GH, Zong MJ, Zhou XY, Chen Y, Han JX. Proteomic
analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in
pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC
Cancer 2008;8:241.
Kreunin P, Zhao J, Rosser C, Urquidi V, Lubman DM, Goodison S. Bladder
cancer associated glycoprotein signatures revealed by urinary
proteomic profiling. J Proteome Res 2007;6:2631-9.
Zibzibadze M, Bochorishvili I, Ramishvili L, Managadze L, Kotrikadze N.
Investigation of pro- and antioxidative systems' changes in blood of
patients with prostate tumours. Georgian Med News 2009:26-9.
Wilczek E, Rzepko R, Nowis D, Legat M, Golab J, Glab M, et al. The
possible role of factor H in colon cancer resistance to complement
attack. Int J Cancer 2008;122:2030-7.
Ajona D, Hsu YF, Corrales L, Montuenga LM, Pio R. Down-regulation of
human complement factor H sensitizes non-small cell lung cancer cells
to complement attack and reduces in vivo tumor growth. J Immunol
2007;178:5991-8.
S206. Ohshiro K, Rosenthal DI, Koomen JM, Streckfus CF, Chambers M,
Kobayashi R, El-Naggar AK. Pre-analytic saliva processing affect
proteomic results and biomarker screening of head and neck squamous
carcinoma. Int J Oncol 2007;30:743-9.
S207. Doustjalali SR, Yusof R, Yip CH, Looi LM, Pillay B, Hashim OH. Aberrant
expression of acute-phase reactant proteins in sera and breast lesions
of patients with malignant and benign breast tumors. Electrophoresis
2004;25:2392-401.
S208. Zhang HY, Sun H. Up-regulation of Foxp3 inhibits cell proliferation,
migration and invasion in epithelial ovarian cancer. Cancer Lett 2009.
S209. Yang L, Peng XH, Wang YA, Wang X, Cao Z, Ni C, et al. Receptor-targeted
nanoparticles for in vivo imaging of breast cancer. Clin Cancer Res
2009;15:4722-32.
S210. Qiu Y, Patwa TH, Xu L, Shedden K, Misek DE, Tuck M, et al. Plasma
glycoprotein profiling for colorectal cancer biomarker identification by
lectin glycoarray and lectin blot. J Proteome Res 2008;7:1693-703.
S211. Zhao J, Patwa TH, Qiu W, Shedden K, Hinderer R, Misek DE, et al.
Glycoprotein microarrays with multi-lectin detection: unique lectin
binding patterns as a tool for classifying normal, chronic pancreatitis
and pancreatic cancer sera. J Proteome Res 2007;6:1864-74.
S212. Bjorge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE,
Meri S. Ascitic complement system in ovarian cancer. Br J Cancer
2005;92:895-905.
S213. Olsson MG, Allhorn M, Olofsson T, Akerstrom B. Up-regulation of
alpha1-microglobulin by hemoglobin and reactive oxygen species in
hepatoma and blood cell lines. Free Radic Biol Med 2007;42:842-51.
S214. Surjit M, Oberoi R, Kumar R, Lal SK. Enhanced alpha1 microglobulin
secretion from Hepatitis E virus ORF3-expressing human hepatoma
cells is mediated by the tumor susceptibility gene 101. J Biol Chem
2006;281:8135-42.
S215. Racila E, Racila DM, Ritchie JM, Taylor C, Dahle C, Weiner GJ. The pattern
of clinical breast cancer metastasis correlates with a single nucleotide
polymorphism in the C1qA component of complement. Immunogenetics
2006;58:1-8.
S216. Hong Q, Sze CI, Lin SR, Lee MH, He RY, Schultz L, et al. Complement C1q
activates tumor suppressor WWOX to induce apoptosis in prostate
cancer cells. PLoS One 2009;4:e5755.
S217. Guilarte M, Luengo O, Nogueiras C, Labrador-Horrillo M, Munoz E, Lopez
A, Cardona V. Acquired angioedema associated with hereditary
angioedema due to C1 inhibitor deficiency. J Investig Allergol Clin
Immunol 2008;18:126-30.
S218. Zheng J, Huang J, Mao Y, Liu S, Sun X, Zhu X, et al. Immunoglobulin gene
transcripts have distinct VHDJH recombination characteristics in
human epithelial cancer cells. J Biol Chem 2009;284:13610-9.
S219. Slizhikova DK, Zinov'eva MV, Kuz'min DV, Snezhkov EB, Shakhparonov
MI, Dmitriev RI, et al. [Decrease in expression of human J-chain in lung
S220.
S221.
S222.
S223.
S224.
S225.
S226.
S227.
S228.
S229.
S230.
S231.
S232.
S233.
squamous cell cancer and adenocarcinoma]. Mol Biol (Mosk)
2007;41:659-65.
Woong-Shick A, Sung-Pil P, Su-Mi B, Joon-Mo L, Sung-Eun N, Gye-Hyun N,
et al. Identification of hemoglobin-alpha and -beta subunits as potential
serum biomarkers for the diagnosis and prognosis of ovarian cancer.
Cancer Sci 2005;96:197-201.
Arpaci A, Gormus U, Dalan B, Berkman S, Isbir T. Investigation of PON1
192 and PON1 55 polymorphisms in ovarian cancer patients in Turkish
population. In Vivo 2009;23:421-4.
Camuzcuoglu H, Arioz DT, Toy H, Kurt S, Celik H, Erel O. Serum
paraoxonase and arylesterase activities in patients with epithelial
ovarian cancer. Gynecol Oncol 2009;112:481-5.
Antognelli C, Del Buono C, Ludovini V, Gori S, Talesa VN, Crino L, et al.
CYP17, GSTP1, PON1 and GLO1 gene polymorphisms as risk factors for
breast cancer: an Italian case-control study. BMC Cancer 2009;9:115.
Singh MK, Pandey UB, Ghoshal UC, Srivenu I, Kapoor VK, Choudhuri G,
Mittal B. Apolipoprotein B-100 XbaI gene polymorphism in gallbladder
cancer. Hum Genet 2004;114:280-3.
Felding-Habermann B, Cheresh DA. Vitronectin and its receptors. Curr
Opin Cell Biol 1993;5:864-8.
Rizzi F, Bettuzzi S. Targeting Clusterin in prostate cancer. J Physiol
Pharmacol 2008;59 Suppl 9:265-74.
Chi KN, Zoubeidi A, Gleave ME. Custirsen (OGX-011): a secondgeneration antisense inhibitor of clusterin for the treatment of cancer.
Expert Opin Investig Drugs 2008;17:1955-62.
Bonanno E, Rulli F, Galata G, Pucci S, Sesti F, Farinon AM, Spagnoli LG.
Stool test for colorectal cancer screening: what is going on? Surg Oncol
2007;16 Suppl 1:S43-5.
Jang JS, Cho HY, Lee YJ, Ha WS, Kim HW. The differential proteome
profile of stomach cancer: identification of the biomarker candidates.
Oncol Res 2004;14:491-9.
al-Ramadi BK, Ellis M, Pasqualini F, Mantovani A. Selective induction of
pentraxin 3, a soluble innate immune pattern recognition receptor, in
infectious episodes in patients with haematological malignancy. Clin
Immunol 2004;112:221-4.
Dieplinger H, Ankerst DP, Burges A, Lenhard M, Lingenhel A, Fineder L,
et al. Afamin and apolipoprotein A-IV: novel protein markers for
ovarian cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1127-33.
Jackson D, Craven RA, Hutson RC, Graze I, Lueth P, Tonge RP, et al.
Proteomic profiling identifies afamin as a potential biomarker for
ovarian cancer. Clin Cancer Res 2007;13:7370-9.
Mohamed E, Abdul-Rahman PS, Doustjalali SR, Chen Y, Lim BK, Omar SZ,
et al. Lectin-based electrophoretic analysis of the expression of the 35
kDa inter-alpha-trypsin inhibitor heavy chain H4 fragment in sera of
patients with five different malignancies. Electrophoresis
2008;29:2645-50.
S234. Gomaa AI, Khan SA, Leen EL, Waked I, Taylor-Robinson SD. Diagnosis of
hepatocellular carcinoma. World J Gastroenterol 2009;15:1301-14.
S235. Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol
Haemost Thromb 2008;36:131-6.
S236. Beecken WD, Bentas W, Engels K, Glienke W, Urbschat A, Jonas D, et al.
Reduced plasma levels of coagulation factors in relation to prostate
cancer. Prostate 2002;53:160-7.
S237. Misao R, Iwagaki S, Sun WS, Fujimoto J, Tamaya T. Levels of
corticosteroid-binding globulin mRNA in human ovarian cancers.
Tumour Biol 1999;20:263-9.
S238. Misao R, Nakanishi Y, Fujimoto J, Ichigo S, Hori M, Tamaya T. Expression
of corticosteroid-binding globulin mRNA in human uterine endometrial
cancers. Steroids 1995;60:720-4.
S239. Mrkonjic M, Chappell E, Pethe VV, Manno M, Daftary D, Greenwood CM,
et al. Association of apolipoprotein E polymorphisms and dietary
factors in colorectal cancer. Br J Cancer 2009;100:1966-74.
S240. Ha SA, Shin SM, Kim HK, Kim S, Namkoong H, Lee YS, et al. Dual action of
apolipoprotein E-interacting HCCR-1 oncoprotein and its implication
for breast cancer and obesity. J Cell Mol Med 2009.
S241. Yan L, Tonack S, Smith R, Dodd S, Jenkins RE, Kitteringham N, et al.
Confounding effect of obstructive jaundice in the interpretation of
proteomic plasma profiling data for pancreatic cancer. J Proteome Res
2009;8:142-8.
S242. Zafar GI, Grimm EA, Wei W, Johnson MM, Ellerhorst JA. Genetic
deficiency of complement isoforms C4A or C4B predicts improved
survival of metastatic renal cell carcinoma. J Urol 2009;181:1028-34;
discussion 34.
S243. Ali OS, Abo-Shadi MA, Hammad LN. The biological significance of serum
complements C3 and C4 in HCV-related chronic liver diseases and
hepatocellular carcinoma. Egypt J Immunol 2005;12:91-9.
S244. Henshall SM, Horvath LG, Quinn DI, Eggleton SA, Grygiel JJ, Stricker PD,
et al. Zinc-alpha2-glycoprotein expression as a predictor of metastatic
prostate cancer following radical prostatectomy. J Natl Cancer Inst
2006;98:1420-4.
S245. Ustach CV, Kim HR. Platelet-derived growth factor D is activated by
urokinase plasminogen activator in prostate carcinoma cells. Mol Cell
Biol 2005;25:6279-88.
S246. Quaresima B, Crugliano T, Gaspari M, Faniello MC, Cosimo P, Valanzano
R, et al. A proteomics approach to identify changes in protein profiles in
serum of Familial Adenomatous Polyposis patients. Cancer Lett
2008;272:40-52.
S247. Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams
E. Acute promyelocytic leukaemia and acquired alpha-2-plasmin
inhibitor deficiency: a retrospective look at the use of epsilonaminocaproic acid (Amicar) in 30 patients. Hematol Oncol
2008;26:241-6.
S248. Gourin CG, Zhi W, Adam BL. Proteomic identification of serum
biomarkers for head and neck cancer surveillance. Laryngoscope
2009;119:1291-302.
S249. Greco M, Mitri MD, Chiriaco F, Leo G, Brienza E, Maffia M. Serum
proteomic profile of cutaneous malignant melanoma and relation to
cancer progression: association to tumor derived alpha-Nacetylgalactosaminidase activity. Cancer Lett 2009;283:222-9.
S250. Schliemann C, Wiedmer A, Pedretti M, Szczepanowski M, Klapper W,
Neri D. Three clinical-stage tumor targeting antibodies reveal
differential expression of oncofetal fibronectin and tenascin-C isoforms
in human lymphoma. Leuk Res 2009.
S251. Pan CW, Shen ZJ, Wu TT, Tang XY, Wang M, Sun J, Shao Y. Cell adhesion
to fibronectin induces mitomycin C resistance in bladder cancer cells.
BJU Int 2009.
S252. Meng XN, Jin Y, Yu Y, Bai J, Liu GY, Zhu J, et al. Characterisation of
fibronectin-mediated FAK signalling pathways in lung cancer cell
migration and invasion. Br J Cancer 2009;101:327-34.
S253. Cheng ZZ, Corey MJ, Parepalo M, Majno S, Hellwage J, Zipfel PF, et al.
Complement factor H as a marker for detection of bladder cancer. Clin
Chem 2005;51:856-63.
S254. Junnikkala S, Jokiranta TS, Friese MA, Jarva H, Zipfel PF, Meri S.
Exceptional resistance of human H2 glioblastoma cells to complementmediated killing by expression and utilization of factor H and factor Hlike protein 1. J Immunol 2000;164:6075-81.
S255. Battistelli S, Stefanoni M, Lorenzi B, Dell'avanzato R, Varrone F, Pascucci
A, et al. Coagulation factor levels in non-metastatic colorectal cancer
patients. Int J Biol Markers 2008;23:36-41.
S256. Biro L, Domjan G, Falus A, Jakab L, Cseh K, Kalabay L, et al. Cytokine
regulation of the acute-phase protein levels in multiple myeloma. Eur J
Clin Invest 1998;28:679-86.
S257. Schlesinger M, Broman I, Lugassy G. The complement system is
defective in chronic lymphatic leukemia patients and in their healthy
relatives. Leukemia 1996;10:1509-13.
S258. Oka R, Sasagawa T, Ninomiya I, Miwa K, Tanii H, Saijoh K. Reduction in
the local expression of complement component 6 (C6) and 7 (C7)
mRNAs in oesophageal carcinoma. Eur J Cancer 2001;37:1158-65.
S259. Lugassy G, Platok I, Schlesinger M. Hypocomplementemia in multiple
myeloma. Leuk Lymphoma 1999;33:365-70.
S260. Begum FD, Hogdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L,
Hogdall C. Preoperative serum tetranectin, CA125 and menopausal
status used as single markers in screening and in a risk assessment
index (RAI) in discriminating between benign and malignant ovarian
tumors. Gynecol Oncol 2009;113:221-7.
S261. Brunner A, Ensinger C, Christiansen M, Heiss S, Verdorfer I, Mikuz G,
Tzankov A. Expression and prognostic significance of Tetranectin in
invasive and non-invasive bladder cancer. Virchows Arch
2007;450:659-64.
S262. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their
advances in proteomics. BMB Rep 2008;41:615-25.
S263. Sauter ER, Scott S, Hewett J, Kliethermes B, Ruhlen RL, Basarakodu K, de
la Torre R. Biomarkers associated with breast cancer are associated
with obesity. Cancer Detect Prev 2008;32:149-55.
S264. Liu W, Liu B, Xin L, Zhang Y, Chen X, Zhu Z, Lin Y. Down-regulated
expression of complement factor I: a potential suppressive protein for
gastric cancer identified by serum proteome analysis. Clin Chim Acta
2007;377:119-26.